DBV Technologies (DBVT) Expected to Post Quarterly Earnings on Wednesday

DBV Technologies (NASDAQ:DBVT) is expected to be issuing its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to announce earnings of ($0.1571) per share and revenue of $0.66 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

DBV Technologies Stock Performance

Shares of DBVT opened at $9.75 on Monday. The company has a market cap of $613.08 million, a PE ratio of -2.78 and a beta of -1.04. The stock has a 50-day moving average price of $11.95 and a 200-day moving average price of $15.38. DBV Technologies has a 12-month low of $8.63 and a 12-month high of $26.18.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Citizens Jmp upped their price objective on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 30th. Citigroup reiterated a “market outperform” rating on shares of DBV Technologies in a research report on Wednesday, September 30th. Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of DBV Technologies in a research note on Thursday, September 10th. Finally, HC Wainwright reissued a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, DBV Technologies has an average rating of “Moderate Buy” and an average target price of $48.50.

DBV Technologies Company Profile

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.